Wednesday, February 28, 2018
from Reuters: Health News http://ift.tt/2BVVmxN
Wednesday, February 28, 2018
Wednesday, February 28, 2018
Unknown
HEALTH NEWS
No comments
(Reuters) - U.S. health regulators have rejected Celgene Corp's application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said on Tuesday, a surprise development that will likely delay the entry to market of one of Celgene's most important pipeline assets.
from Reuters: Health News http://ift.tt/2BVVmxN
from Reuters: Health News http://ift.tt/2BVVmxN
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment